Association between worsening time in range and microvascular complications in type 1 diabetes: real-world 5-year study

Clicks: 12
ID: 328768
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #423 of 449 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 449 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
CONTEXT: Beyond HbA1c, continuous glucose monitoring (CGM) is now widely used in clinical practice, providing more detailed information about glycemic control. However, its ability to predict long-term microvascular outcomes in type 1 diabetes remains unclear. OBJECTIVE: To evaluate the association between CGM-derived glucometrics and the 5-year incidence of microvascular complications, providing longitudinal real-world evidence in adults with type 1 diabetes. DESIGN: Longitudinal real-world cohort study with five-year follow-up. SETTING: Tertiary referral center. PARTICIPANTS: 246 adults with type 1 diabetes (median age 40 [28-53] years, diabetes duration 24 [13-33] years). INTERVENTION: No interventional treatment. MAIN OUTCOME MEASURE: Composite microvascular endpoint including nephropathy (persistent albuminuria ≥20 µg/min, eGFR <60 mL/min/1.73 m2, and/or RAAS inhibitor use for albuminuria), severe retinopathy (proliferative retinopathy, maculopathy, and/or blindness), and peripheral neuropathy (monofilament score <6/6 and/or abnormal nerve conduction). RESULTS: HbA1c decreased from 7.6% (59 mmol/mol) to 7.2% (55 mmol/mol), and time in range (TIR, 70-180 mg/dL) increased from 50 ± 14% to 61 ± 15%. All CGM-derived metrics (TIR, mean glucose, glucose management indicator) were associated with the composite endpoint. In this longitudinal real-world cohort, a ≥ 10% decrease in TIR was associated with higher complication rates (33.3%) compared with a stable TIR (7.9%) or ≥10% increase (15.0%) (p = 0.011). In multivariable analyses adjusted for age and baseline TIR, change in TIR (ΔTIR) remained independently associated with outcomes. BMI and systolic blood pressure were not significant. Models incorporating glucometrics and age showed acceptable discriminative performance (AUCs 0.757-0.787). CONCLUSIONS: CGM-derived glucometrics were associated with the 5-year incidence of microvascular complications in this real-world cohort, with ΔTIR potentially providing additional prognostic information beyond HbA1c. Further validation is needed before routine clinical implementation.
Reference Key
openalex_W7212311394 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Amber Sabbe, Niels Bochanen, Annelies Van den Broucke, Katarina Mihaljčić, Axelle Bigaré, Kristof Van Dessel, Jason Bouziotis, Kristien J. Ledeganck, Eveline Dirinck, Nancy Bolsens, Jolien De Meulemeester, Pieter Gillard, Christophe De Block
Are you one of these authors? Claim your profile
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag380
URL
https://doi.org/10.1210/clinem/dgag380
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.